Literature DB >> 19317256

Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents.

C Liebrich1, O Brummer, R Von Wasielewski, G Wegener, C Meijer, T Iftner, K U Petry.   

Abstract

Cancer of the uterine cervix is almost exclusively associated with human papillomavirus (HPV). Carcinogenesis is slow, the minimal time from initial HPV infection to invasive carcinoma seems to be less than ten years. In order to identify rapid onset cervical cancer, we carried out a retrospective re-analysis of an extended cohort of patients with invasive cervical cancer, and reviewed cases identified within the cancer registry of Lower Saxony or using Medline or ISI data. No instances of a rapid-onset cancer or true HPV-DNA negative cancer were found among our hospital cohort of 178 women with primary cancer of the uterine cervix. Registry data identified four out of 5,878 patients who were diagnosed with primary cervical cancer at 14 to 20 years of age. They were classified as clear-cell and endometriod adenocarcinoma and tested persistently negative for high-risk HPV-DNA. Fourteen more cases of cervical cancer in virgins and very young women were identified by a Medline search, mostly with unknown histologic type or rare subtypes of adenocarcinoma. In conclusion, rare adenocarcinoma of the uterine cervix may represent an entity unrelated to HPV, thus explaining instances of rapid onset cervical cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19317256

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  9 in total

Review 1.  The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero.

Authors:  Monica M Laronda; Kenji Unno; Lindsey M Butler; Takeshi Kurita
Journal:  Differentiation       Date:  2012-06-06       Impact factor: 3.880

Review 2.  Recreating the female reproductive tract in vitro using iPSC technology in a linked microfluidics environment.

Authors:  Monica M Laronda; Joanna E Burdette; J Kim; Teresa K Woodruff
Journal:  Stem Cell Res Ther       Date:  2013-12-20       Impact factor: 6.832

Review 3.  Normal and abnormal epithelial differentiation in the female reproductive tract.

Authors:  Takeshi Kurita
Journal:  Differentiation       Date:  2011-05-25       Impact factor: 3.880

4.  US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.

Authors:  Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman
Journal:  J Natl Cancer Inst       Date:  2015-04-29       Impact factor: 13.506

5.  Clear Cell Carcinoma of Cervix in a 60- year-old Woman: A Case Report.

Authors:  Kumar Ramesh; Shruthi S A; Saraswati P; Rathnamala M Desai; Anil K
Journal:  J Clin Diagn Res       Date:  2014-08-20

6.  Is human papillomavirus genotype an influencing factor on radiotherapy outcome? Ambiguity caused by an association of HPV 18 genotype and adenocarcinoma histology.

Authors:  Joo-Young Kim; Byung Ho Nam; Jin-Ah Lee
Journal:  J Gynecol Oncol       Date:  2011-03-31       Impact factor: 4.401

7.  Clear cell carcinoma of cervix in a postmenopausal woman: A case report.

Authors:  Subrata Pal; Sritanu Jana; Kingshuk Bose
Journal:  J Midlife Health       Date:  2015 Apr-Jun

8.  Evaluating HPV-negative CIN2+ in the ATHENA trial.

Authors:  Karl Ulrich Petry; J Thomas Cox; Kristin Johnson; Wim Quint; Ruediger Ridder; Mario Sideri; Thomas C Wright; Catherine M Behrens
Journal:  Int J Cancer       Date:  2016-03-02       Impact factor: 7.396

9.  Effectiveness, structure, and content of nurse counseling in gynecologic oncology: a systematic review.

Authors:  Silvia Raphaelis; Andrea Kobleder; Hanna Mayer; Beate Senn
Journal:  BMC Nurs       Date:  2017-08-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.